Northeast Pharmaceutical Group (000597) Fair Value & Analysis
Healthcare · CN · Market cap 6.6B CNY
Analysis
Northeast Pharmaceutical Group (000597) currently trades at ¥4.42, while our model-based Fair Value estimate is ¥6.57 — implying the stock looks roughly 48.6% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali hydrochloride, chloramphenicol, and other products; and reproductive system and hormone products comprising carboprost suppositories, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. It also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; narcotics and psychotropic drugs and related products, including morphine hydrochloride injections and tablets, oxycodone hydrochloride injection, compound glycyrrhiza series, and acetaminophen-codeine tablets; anti-AIDS products comprising Krughar…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.